Thymocytes May Persist and Differentiate Without Any Input from Bone Marrow Progenitors

Total Page:16

File Type:pdf, Size:1020Kb

Thymocytes May Persist and Differentiate Without Any Input from Bone Marrow Progenitors Brief Definitive Report Thymocytes may persist and differentiate without any input from bone marrow progenitors Laetitia Peaudecerf,1 Sara Lemos,1 Alessia Galgano,1 Gerald Krenn,1 Florence Vasseur,1 James P. Di Santo,2 Sophie Ezine,1 and Benedita Rocha1 1Institut National de la Santé et de la Recherche Médicale, Unit 1020, Faculty of Medicine Descartes Paris V, 75015 Paris, France 2Innate Immunity Unit, Pasteur Institute, 75724 Paris, France Thymus transplants can correct deficiencies of the thymus epithelium caused by the com- plete DiGeorge syndrome or FOXN1 mutations. However, thymus transplants were never used to correct T cell–intrinsic deficiencies because it is generally believed that thymocytes have short intrinsic lifespans. This notion is based on thymus transplantation experiments where it was shown that thymus-resident cells were rapidly replaced by progenitors origi- nating in the bone marrow. In contrast, here we show that neonatal thymi transplanted into interleukin 7 receptor–deficient hosts harbor populations with extensive capacity to self-renew, and maintain continuous thymocyte generation and export. These thymus transplants reconstitute the full diversity of peripheral T cell repertoires one month after surgery, which is the earliest time point studied. Moreover, transplantation experiments performed across major histocompatibility barriers show that allogeneic transplanted thymi are not rejected, and allogeneic cells do not induce graft-versus-host disease; transplants induced partial or total protection to infection. These results challenge the current dogma that thymocytes cannot self-renew, and indicate a potential use of neonatal thymus trans- plants to correct T cell–intrinsic deficiencies. Finally, as found with mature T cells, they show that thymocyte survival is determined by the competition between incoming progeni- tors and resident cells. CORRESPONDENCE T lymphocytes are fundamental for the control cannot correct T cell deficiencies once the thy- Benedita Rocha: of infection. In rare cases, T cell deficiencies mus atrophies in adults. [email protected] are congenital, caused by mutations preventing Thymus transplants could constitute an The Journal of Experimental Medicine Abbreviations used: DP, the expression of any gene required for T cell advantageous alternative or complementary CD4+CD8+ double-positive generation. However, in most cases they are therapy; these grafts could be a source of both thymocytes; GVH, graft- induced in the adult either by infections such as a functional thymus epithelia and functional versus-host; LM, Listeria mono- cytogenes; LSK, Lineage Sca-1+ AIDS, by aggressive anticancer therapies, or by T cells, and thus might correct T cell deficien- c-Kit+ BM precursors; TN, aging. In the current clinical practice, these sit- cies in both children and adults. They would Lineage CD4CD8CD3 uations have become frequent, rendering the not necessarily require the conditioning of the triple-negative thymocyte. reconstitution of the peripheral T cell pool an patient and should export mature T cells im- important clinical goal. In children who do not mediately, overcoming the long lag-time re- yet have competent thymus epithelia, T cell quired for thymus T cell generation after BM reconstitution may be achieved by the trans- transplantation. However, although thymus grafts plantation of a competent BM. However, because were successful in correcting deficiencies of the BM precursors must transit through the thy- thymus epithelium, as found in the complete mus to generate T cells, the peripheral T cell DiGeorge syndrome (Markert et al., 2007) or reconstitution is delayed by many months, during which time patients are very susceptible to infec- © 2012 Peaudecerf et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six tions (Parkman and Weinberg, 1997; Holländer, months after the publication date (see http://www.rupress.org/terms). After six months 2008; Cavazzana-Calvo et al., 2009; Reimann it is available under a Creative Commons License (Attribution–Noncommercial– Share Alike 3.0 Unported license, as described at http://creativecommons.org/ et al., 2010). In addition, BM transplantation licenses/by-nc-sa/3.0/). The Rockefeller University Press $30.00 J. Exp. Med. 2012 Vol. 209 No. 8 1401-1408 1401 www.jem.org/cgi/doi/10.1084/jem.20120845 in FOXN1 mutations (Markert et al., 2011), they were never Mechanisms involved in autonomous thymocyte renewal used to correct intrinsic T cell deficiencies, as it is generally Several possibilities could explain the persistence of resident accepted that the thymus does not harbor precursors with self- thymocytes in the thymus transplants grafted into IL-7R– renewal capacities. Indeed, in thymus transplants, resident deficient hosts. We excluded contamination by circulating thymocytes generate a single wave of mature T cells because hematopoietic stem cells, thereby ensuring continuous graft precursors originating from the BM rapidly replace resident colonization. The host BM did not contain CD45.1+ precur- cells (Berzins et al., 1998). Moreover, this occurs even when sors derived from the graft; the only precursors present were the host cannot generate mature T cells. When WT thymi are CD45.2+ ; LSK, Lineage Sca-1+c-Kit+ BM precursors (LSKs) transplanted into SCID or Rag2-deficient hosts, the compe- from the host, as it is characteristic for Rag IL-7R or Ragc tent thymocyte populations from the graft are rapidly re- mice (Fig. 1 C). Thymocyte persistence was also not caused by placed by the incompetent precursors from the host BM any mechanism preventing the colonization of the graft by (Frey et al., 1992; Takeda et al., 1996), and mature T cell ex- the host BM: all grafts were colonized by host BM-derived port fails by 3 wk after surgery. Based on these data, the cur- progenitors, which progressed through differentiation as char- rent dogma postulates that all thymocyte subpopulations are acteristic of each set of host mice: WT BM generating all short-lived, with their maintenance being strictly dependent Lineage CD4CD8CD3 triple-negative thymocytes on the continuous input of BM-derived progenitors. (TN) precursor types, Rag2 BM-derived cells arresting their In contrast, we describe that the neonatal thymus harbors differentiation at the TN3, and IL-7R or Ragc BM at populations with self-renewal capacity that maintain the thymo- the TN2 differentiation stage (Fig. 1 D; Egerton et al., 1990; cyte populations independently of any input from the BM, Mombaerts et al., 1992; Di Santo et al., 1999). Finally, Ly5.1+ rapidly reconstitute the peripheral T cell pools, and the ca- thymocytes of graft origin could have stopped dividing, but pacity to clear infections in T cell–deficient mice. Moreover, this was not the case (Fig. 2): we concluded that the persis- these transplants function across histocompatibility barriers, tence of a conserved CD4+/CD8+ profile in the trans- recalling early studies on the susceptibility of neonatal cells to planted thymi indicated the presence of one or several become tolerant to alloantigens (Billingham et al., 1953). populations with self-renewal capacity. These results highlight a possible application of thymus trans- We first considered that CD4+CD8+ double-positive plants in correcting intrinsic T cell deficiencies. thymocytes(DP) cells might continuously renew in the ab- sence of any intake from more immature precursors, although RESULTS AND DISCUSSION their BrdU incorporation was similar to that of DP cells from The fate of thymus transplants in IL-7R–deficient hosts a normal thymus (Fig. 2 A). To address this possibility, we When searching for thymocyte populations able to generate investigated DP cells’ TCRA repertoires, as the continuous gut intraepithelial lymphocytes (Lambolez et al., 2006; division of the same cohort of DP cells should reduce diver- Peaudecerf et al., 2011) we found that thymus transplants be- sity and/or switch TCRA repertoires to the preferential usage haved differently when transplanted into Ragc hosts. Indeed, of 5 V and 3 J genes (Guo et al., 2002; Pasqual et al., as described previously (Berzins et al., 1998), when a single 2002; Krangel et al., 2004). However, the high-throughput neonatal CD45.1+ thymus lobe is grafted into WT CD45.2+ analysis of 107 TCRA chains expressed by normal DP thymo- hosts, the transplant is rapidly invaded by precursor cells de- cytes and 8 × 106 TCRA chains expressed by DP cells from rived from the host BM; 1 mo later, only rare mature T cells transplanted thymi showed no modifications of TCRA from the graft remain (Fig. 1 A). This substitution occurs repertoires (Fig. S1). Diversity was maintained because sam- even when the host cannot generate mature T cells (Frey ples had equivalent number of unique in-frame CDR3s et al., 1992; Takeda et al., 1996); when CD45.1+ thymi are (Fig. S1 A), and VA and JA usage were also comparable transplanted into CD45.2+ Rag2- or CD3-deficient mice (Fig. S1 B). Therefore, DP differentiation was not modified, (not depicted) thymocytes of graft origin are also substi- indicating that maintenance of DP cells in these grafts should tuted by incompetent CD45.2+ precursors from the host be ensured by more immature progenitors. BM (Fig. 1 A). In contrast, we were surprised to observe that Analysis of CD45.1+ TN cells revealed the persistence of this substitution did not occur when the hosts could not re- T cell progenitors of graft origin. Resident ETPs and TN2s + spond to IL-7; in CD45.2 Rag2 IL-7R or Rag2c hosts, declined rapidly (Fig. 2 B), likely substituted by the hosts’ the vast majority of thymocytes residing in the graft were TN precursors (Fig. 1 D). CD45.1+ TNs were progressively CD45.1+ cells of graft origin (Fig. 1 A). These resident cells enriched in CD44+CD25low TN1–TN2 transition cells, with persisted and maintained a normal CD4/CD8 profile up a CD44+ Sca-1+ c-kit+ IL-7Rlow, Fl3L+/ phenotype (Fig. 2, to 7 mo after transplant, the latest time point studied (Fig.
Recommended publications
  • Strokovno Poročilo UKCL 2019
    STROKOVNO POROČILO 2019 STROKOVNO POROČILO 2019 Univerzitetni klinični center Ljubljana, Zaloška cesta 2, 1000 Ljubljana Odgovorna oseba: prof. dr. Jadranka Buturović Ponikar, dr. med., strokovna direktorica UKC Ljubljana Besedila za poročilo so prispevali: prof. dr. Zlatko Fras, mag. Jana Brguljan Hitij, prof. dr. Aleš Blinc, prof. dr. Matjaž Šinkovec, prof. dr. Marko Noč, prof. dr. Marjeta Terčelj, prof. dr. Borut Štabuc, prof. dr. Miha Arnol, doc. dr. Andrej Janež, prof. dr. Samo Zver, prof. dr. Matija Tomšič, Gregor Veninšek, doc. dr. Miran Brvar, dr. Hugon Možina, prof. dr. Matjaž Veselko, dr. Nikola Lakić, prof. dr. Roman Bošnjak, prof. dr. Uroš Ahčan, prof. dr. Matej Cimerman, prof. dr. Aleš Tomažič, dr. Tomaž Štupnik, asist. Bojan Štrus, prof. dr. Andrej Kansky, prof. dr. Vesna Novak Jankovič, doc. dr. Igor Frangež, prof. dr. Simon Podnar, prof. dr. Uroš Rot, doc., prof. dr. Adolf Lukanovič, doc. dr. Borut Kobal, Mag. Gorazd Kavšek, prof. dr. Eda Vrtačnik Bokal, Leon Meglič, prof. dr. Borut Peterlin, doc.dr. Marko Pokorn, doc. dr. Anamarija Meglič, prim. Mojca Brecelj Kobe, prof. dr.Tadej Avčin, Uroš Krivec, prof. dr. Rok Orel, prof. dr. Tadej Battellino, prof. dr. Tanja Kersnik Levart, prof. dr. Janez Jazbec, prof. dr. Darja Paro Panjan, prof. dr. David Neubauer, mag. Mojca Tomažič, asist. dr. Veronika Velenšek, prof. dr. Milan Petelin, prof. dr. Martina Drevenšek, dr. Rok Kosem, doc.dr. Milan Kuhar, doc. dr. Tatjana Lejko Zupanc, prof. dr. Mojca Globočnik Petrović, prof. dr. Vane Antolič, doc. dr. Aleksandar Aničin, prim. asist. Tanja Planinšek Ručigaj, doc.dr.. Dimitrij Kuhelj, doc. dr. Katja Zaletel, prof. dr. Milan Skitek, prof.
    [Show full text]
  • Newsletteralumni News of the Newyork-Presbyterian Hospital/Columbia University Department of Surgery Volume 13, Number 1 Summer 2010
    NEWSLETTERAlumni News of the NewYork-Presbyterian Hospital/Columbia University Department of Surgery Volume 13, Number 1 Summer 2010 CUMC 2007-2009 Transplant Activity Profile* Activity Kidney Liver Heart Lung Pancreas Baseline list at year start 694 274 174 136 24 Deceased donor transplant 123 124 93 57 11 Living donor transplant 138 17 — 0 — Transplant rate from list 33% 50% 51% 57% 35% Mortality rate while on list 9% 9% 9% 15% 0% New listings 411 217 144 68 23 Wait list at year finish 735 305 204 53 36 2007-June 2008 Percent 1-Year Survival No % No % No % No % No % Adult grafts 610 91 279 86 169 84 123 89 6 100 Adult patients 517 96 262 88 159 84 116 91 5 100 Pediatric grafts 13 100 38 86 51 91 3 100 0 — Pediatric patients 11 100 34 97 47 90 2 100 0 — Summary Data Total 2009 living donor transplants 155 (89% Kidney) Total 2009 deceased donor transplants 408 (30% Kidney, 30% Liver) 2007-June 2008 adult 1-year patient survival range 84% Heart to 100% Pancreas 2007-June 2008 pediatric 1-year patient survival range 90% Heart to 100% Kidney or lung *Health Resource and Service Administration’s Scientific Registry of Transplant Recipients (SRTR) Ed Note. The figure shows the US waiting list for whole organs which will only be partially fulfilled by some 8,000 deceased donors, along with 6,600 living donors, who will provide 28,000 to 29,000 organs in 2010. The Medical Center’s role in this process is summarized in the table, and the articles that follow my note expand on this incredible short fall and its potential solutions.
    [Show full text]
  • Transplanted Thymus Thymus Nor the Development of Impairs Neither the Recovery of Recipient Depleted Lymphocyte Infusion
    CD4+ T Cell −Depleted Lymphocyte Infusion Impairs Neither the Recovery of Recipient Thymus nor the Development of Transplanted Thymus This information is current as of September 26, 2021. Ming Shi, Ming Li, Yunze Cui, Lin Liu, Yasushi Adachi and Susumu Ikehara J Immunol 2013; 190:2976-2983; Prepublished online 4 February 2013; doi: 10.4049/jimmunol.1201605 Downloaded from http://www.jimmunol.org/content/190/6/2976 Supplementary http://www.jimmunol.org/content/suppl/2013/02/04/jimmunol.120160 http://www.jimmunol.org/ Material 5.DC1 References This article cites 36 articles, 10 of which you can access for free at: http://www.jimmunol.org/content/190/6/2976.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 26, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Author Choice Freely available online through The Journal of Immunology Author Choice option Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology CD4+ T Cell–Depleted Lymphocyte Infusion Impairs Neither the Recovery of Recipient Thymus nor the Development of Transplanted Thymus Ming Shi,* Ming Li,* Yunze Cui,*,† Lin Liu,* Yasushi Adachi,*,‡ and Susumu Ikehara* Thymus transplantation, in conjunction with bone marrow transplantation (BMT), has been attracting attention for the treatment of various diseases.
    [Show full text]
  • Thymus Transplantation Reference Number: CP.MP.189 Coding Implications Date of Last Revision: 06/21 Revision Log
    Clinical Policy: Thymus Transplantation Reference Number: CP.MP.189 Coding Implications Date of Last Revision: 06/21 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Complete DiGeorge anomaly is a disorder in which a person has no thymus function. Without thymus function, bone marrow stem cells do not develop into T cells, which results in immunodeficiency. Without successful treatment, patients usually die by 2 years of age. Thymus transplantation with and without immunosuppression has resulted in the development good T cell function in complete DiGeorge anomaly subjects.1 Policy/Criteria I. It is the policy of health plans affiliated with Centene Corporation® that thymus transplant (use of RVT-802) requires secondary review, due to limited evidence, when meeting all of the following: A. Complete or “atypical” DiGeorge syndrome with poor thymus function, per medical testing laboratory studies and physical examination, as confirmed by the thymus transplant clinical trial (NCT01220531); B. Immunodeficiency, or severe autoimmunity for which development of naïve T cells would be expected to lead to clinical improvement; C. Flow cytometry and phytohaemagglutinin (PHA) studies are planned to occur twice, once within 3 months of transplantation and once within one month of transplantation. Studies must be performed in a CLIA or CAP certified laboratory, preferably Duke Clinical Immunology Laboratory; D. None of the following contraindications: 1. Malignancy, except for non-melanoma localized skin cancer that has been treated appropriately, a malignancy that has been completely resected, or a treated malignancy determined to have a small likelihood of recurrence and acceptable future risks; 2.
    [Show full text]
  • Results of Gal-Knockout Porcine Thymokidney Xenografts
    Results of Gal-Knockout Porcine Thymokidney Xenografts The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Griesemer, A. D., A. Hirakata, A. Shimizu, S. Moran, A. Tena, H. Iwaki, Y. Ishikawa, et al. 2009. “Results of Gal-Knockout Porcine Thymokidney Xenografts.” American Journal of Transplantation 9 (12) (December): 2669–2678. doi:10.1111/j.1600-6143.2009.02849.x. Published Version doi:10.1111/j.1600-6143.2009.02849.x Citable link https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37364476 Terms of Use This article was downloaded from Harvard University’s DASH repository, WARNING: This file should NOT have been available for downloading from Harvard University’s DASH repository.;This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/ urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA NIH Public Access Author Manuscript Am J Transplant. Author manuscript; available in PMC 2010 November 20. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Am J Transplant. 2009 December ; 9(12): 2669±2678. doi:10.1111/j.1600-6143.2009.02849.x. Results of Gal-Knockout porcine thymokidney xenografts Adam D. Griesemer1, Atsushi Hirakata1, Akira Shimizu1, Shannon Moran1, Aseda Tena1, Hideyuki Iwaki1, Yoshinori Ishikawa1, Patrick Schule1, J. Scott Arn1, Simon C. Robson2, Jay A. Fishman3, Megan Sykes1, David H. Sachs1, and Kazuhiko Yamada1,4 1Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 2Transplant Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 3Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
    [Show full text]
  • Hematopoietic Stem Cell Transplantation for 30 Patients with Primary Immunodeficiency Diseases: 20 Years Experience of a Single Team
    Bone Marrow Transplantation (2006) 37, 469–477 & 2006 Nature Publishing Group All rights reserved 0268-3369/06 $30.00 www.nature.com/bmt ORIGINAL ARTICLE Hematopoietic stem cell transplantation for 30 patients with primary immunodeficiency diseases: 20 years experience of a single team Y Tsuji1, K Imai1,2, M Kajiwara1,3, Y Aoki1, T Isoda1, D Tomizawa1, M Imai1, S Ito1, H Maeda1, Y Minegishi1, H Ohkawa1, JYata 1, N Sasaki4, K Kogawa2, M Nagasawa1, T Morio1, S Nonoyama2 and S Mizutani1 1Department of Pediatrics and Developmental Biology, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan; 2Department of Pediatrics, National Defense Medical College, Saitama, Japan; 3Department of Blood Transfusion, University Hospital Faculty of Medicine, Tokyo Medical and Dental University, Tokyo, Japan and 4Department of Pediatrics, Saitama Medical School, Saitama, Japan We retrospectively analyzed our results of 30 patients with Introduction three distinctive primary immunodeficiency diseases (PIDs) – severe combined immunodeficiency (SCID, n ¼ 11), Primary immunodeficiency diseases (PIDs) are often Wiskott–Aldrich syndrome (WAS, n ¼ 11) and X-linked accompanied with life-threatening infections. Hematopoie- hyper-immunoglobulin M (IgM) syndrome (XHIM, n ¼ 8) tic SCT (HSCT) can be a treatment of choice to cure most – who underwent hematopoietic SCT (HSCT) during the of the lethal forms of immunodeficiencies, including severe past 20 years. Until 1995, all donors were HLA- combined immunodeficiency (SCID), Wiskott–Aldrich haploidentical relatives with T-cell depletion (TCD) syndrome (WAS) and X-linked hyper immunoglobulin M (n ¼ 8). Since 1996, the donors have been HLA-matched (IgM) syndrome (XHIM). An HLA-matched related donor related donors (MRD) (n ¼ 8), unrelated BM (UR-BM) (MRD), the best hematopoietic stem cell source, may not (n ¼ 7) and unrelated cord blood (UR-CB) (n ¼ 7).
    [Show full text]
  • Selected Abstracts from the 12 Annual
    Journal of Clinical Immunology (2021) 41 (Suppl 1):S1–S135 https://doi.org/10.1007/s10875-021-01001-x ABSTRACTS Selected Abstracts from the 12th Annual Meeting of the Clinical Immunology Society: 2021 Virtual Annual Meeting: Immune Deficiency and Dysregulation North American Conference Published online: 6 April 2021 # Springer Science+Business Media, LLC, part of Springer Nature 2021 Virtual, April 14-17 The study samples were cleared cryo-poor plasma. A chromatographic process using a new cation-exchange (CEX) resin that binds with high Sponsorship: Publication of this supplement was funded by the capacity to IgG and removes procoagulant activities was added in a se- Clinical Immunology Society. All content was reviewed and approved quential step to the standard removal/inactivation process. Testing of the by the Program Committee, which held full responsibility for the samples was performed using the standard process alone and then with abstract selections. sequential addition of the new CEX process. Procoagulant activity was tested using several standard methods, including, thrombin generation All contributors have provided original material assay, chromogenic FXIa assay, non-activated partial thromboplastin as submitted for publication in the Journal time (NaPTT), and FXI/FXIa ELISA. We further spiked our samples with of Clinical Immunology. additional coagulation factor XIa, in amounts exceeding any variability that may be caused due to sample differences, and tested these samples 01 Oral Presentations for procoagulant activity using the same methods. The procoagulant activities were reduced to low levels as determined by the thrombin generation assay: < 1.56 mIU/mL, chromogenic FXIa assay: < 0.16 mIU/mL, NaPTT: >250 s, FXI/FXIa ELISA: < 0.31 ng/mL.
    [Show full text]
  • T-Cell Reconstitution After Thymus Xenotransplantation Induces Hair Depigmentation and Loss Anna L
    ORIGINAL ARTICLE T-Cell Reconstitution after Thymus Xenotransplantation Induces Hair Depigmentation and Loss Anna L. Furmanski1, Ryan F.L. O’Shaughnessy1, Jose Ignacio Saldana1, Michael P. Blundell2, Adrian J. Thrasher2,NeilJ.Sebire3,E.GrahamDavies2,4 and Tessa Crompton1 Here we present a mouse model for T-cell targeting of hair follicles, linking the pathogenesis of alopecia to that of depigmentation disorders. Clinically, thymus transplantation has been successfully used to treat T-cell immunodeficiency in congenital athymia, but is associated with autoimmunity. We established a mouse model of thymus transplantation by subcutaneously implanting human thymus tissue into athymic C57BL/6 nude mice. These xenografts supported mouse T-cell development. Surprisingly, we did not detect multiorgan autoimmune disease. However, in all transplanted mice, we noted a striking depigmentation and loss of hair follicles. Transfer of T cells from transplanted nudes to syngeneic black-coated RAG À / À recipients caused progressive, persistent coat-hair whitening, which preceded patchy hair loss in depigmented areas. Further transfer experiments revealed that these phenomena could be induced by CD4 þ T cells alone. Immunofluorescent analysis suggested that Trp2 þ melanocyte-lineage cells were decreased in depigmented hair follicles, and pathogenic T cells upregulated activation markers when exposed to C57BL/6 melanocytes in vitro, suggesting that these T cells are not tolerant to self-melanocyte antigens. Our data raise interesting questions about the mechanisms underlying tissue-specific tolerance to skin antigens. Journal of Investigative Dermatology (2013) 133, 1221–1230; doi:10.1038/jid.2012.492; published online 10 January 2013 INTRODUCTION et al., 2007). Autoimmune vitiligo in humans typically Alopecia is a disfiguring form of hair loss, which may be presents as patchy skin depigmentation resulting from a reversible, or irreversible, as in scarring alopecias.
    [Show full text]
  • Division of Immunogenetics Division of Immunogenetics
    DIVISION OF IMMUNOGENETICS diVision of ImmunoGenetics Mission The Division of Immunogenetics is committed to providing basic science support aimed at better understanding the etio-pathogenesis of pediatric diseases to more efficiently and correctly diagnose, prevent, and possibly 136 better treat them. 137 DEPARTMENT OF PEDIATRICS 2012 ANNUAL REPORT DEPARTMENT OF PEDIATRICS 2012 ANNUAL REPORT DIVISION OF IMMUNOGENETICS DIVISION OF IMMUNOGENETICS facultY AND staff To block auto-immunity, without the use of immunosuppressant, Nick Giannoukakis and Massimo Trucco have success- fully completed a National Institutes of Health (NIH)-funded, U.S. Food and Drug Administration (FDA)-approved Massimo Trucco, MD Yong Fan, PhD Steven Ringquist, PhD phase I clinical trial that was designed to test the safety of a treatment in which autologous DC—rendered functionally Hillman Professor of Research Assistant Professor Research Assistant Professor immature by exposing them to CD40, CD80, and CD86 antisense oligodeoxyribonucleotides (AS-ODN) to reduce Pediatric Immunology costimulatory molecule levels at their surface—were administered to T1D patients with established disease. Leukocytes Nick Giannoukakis, PhD William Rudert, MD, PhD of the patient were obtained by apheresis, and DCs were then isolated and expanded. DC engineered in GMP facilities Suzanne Bertera, PhD Associate Professor Research Associate Professor to express low levels of CD40, CD80, and CD86 were then injected into the patient by intradermal administration at an Research Assistant Professor Jing He, MD, PhD Tatyana Votyakova, MD, PhD anatomical site proximal to the pancreas. DCs then migrate to the nearest (i.e., pancreatic) lymph nodes, where they are Rita Bottino, PhD Research Assistant Professor Research Assistant Professor able to interrupt the vicious circle that maintains islet-specific inflammation (i.e., insulitis).
    [Show full text]
  • Memory-Enriched Population Aged Microenvironment Results in a Lymphocytes in the + Maturation Of
    Maturation of CD4+ Lymphocytes in the Aged Microenvironment Results in a Memory-Enriched Population This information is current as Jenna A. Timm and Marilyn L. Thoman of September 25, 2021. J Immunol 1999; 162:711-717; ; http://www.jimmunol.org/content/162/2/711 Downloaded from References This article cites 44 articles, 19 of which you can access for free at: http://www.jimmunol.org/content/162/2/711.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 25, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 1999 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Maturation of CD41 Lymphocytes in the Aged Microenvironment Results in a Memory-Enriched Population1 Jenna A. Timm and Marilyn L. Thoman2 With advancing age the CD41 T lymphocyte compartment becomes enriched for memory cells in both humans and experimental animals. Although it has been assumed that the shift from a naive to a memory-dominant population is due to a lifetime of antigenic exposure and selection as well as a loss of naive cell input due to reduced thymopoiesis, the present data suggest that the aged microenvironment influences the maturation of newly produced CD41 T cells.
    [Show full text]
  • FINAL PROGRAM DAY 1 - August 18 DAY 2 - August 19 DAY 3 - August 20
    FINAL PROGRAM DAY 1 - August 18 DAY 2 - August 19 DAY 3 - August 20 Registration (all day) Registration (all day) Registration (all day) Early Morning Symposia 07:00–08:15 Post- Pre- Post-Graduate Plenary Session 1: Graduate Congress Courses Basic and Translational Courses Meeting 08:30–13:00 Sciences 08:30–13:00 14:00–17:30 14:00–17:30 TID 2016 08:30–10:00 Conference 08:30–18:00 Co"ee Break 10:00–10:30 Orals and Mini-Orals Sessions 10:30–12:30 Lunch Break / Industry Exhibition Symposium Exhibition Set-up Exhibition Set-up 12:30–13:30 12:30–13:30 State-of-the-Art Sessions Exhibition 13:30–15:00 Co"ee Break 15:00–15:30 Orals Sessions 15:30–17:00 WIT Camp!re Wkshop and & Net. Poster Event Sessions Opening Ceremony Industry 17:00– 17:00– 17:30–18:30 Symp. 19:00 18:30 17:30– 19:00 Welcome Reception 18:30–20:00 Exhibition Young Investigators’ Networking Event 19:30–21:30 (ticketed) DAY 4 - August 21 DAY 5 - August 22 DAY 6 - August 23 Registration (all day) Registration (all day) Registration (all day) Early Morning Symposia Early Morning Symposia Early Morning Symposia 07:00–08:15 07:00–08:15 07:00–08:15 Plenary Session 2: Plenary Session 3: Plenary Session 4: Antibody Mediated Injury Hepatitis C Virus in Transformational Sciences Solid Organ Transplantation: in Transplantation? Have the Rules Changed? 08:30–10:00 08:30–10:00 08:30–10:00 Co!ee Break Co!ee Break Co!ee Break 10:00–10:30 10:00–10:30 10:00–10:30 Orals and Mini-Orals President’s Plenary Orals Sessions and Awards Sessions 10:30–12:30 10:30–12:30 10:30–12:00 Plenary Session 5: What
    [Show full text]
  • Thymic Rejuvenation and the Induction of Tolerance by Adult Thymic Grafts
    Thymic rejuvenation and the induction of tolerance by adult thymic grafts Shuji Nobori, Akira Shimizu, Masayoshi Okumi, Emma Samelson-Jones, Adam Griesemer, Atsushi Hirakata, David H. Sachs, and Kazuhiko Yamada* Transplantation Biology Research Center, Massachusetts General Hospital/Harvard Medical School, Boston, MA 02129 Edited by Ralph M. Steinman, The Rockefeller University, New York, NY, and approved October 25, 2006 (received for review June 22, 2006) The thymus, the site of origin of T cell immunity, shapes the repertoire procedure and then facilitated the induction of tolerance, suggest- of T cell reactivity through positive selection of developing T cells and ing that thymic function is largely controlled by the host environ- prevents autoimmunity through negative selection of autoreactive T ment rather than by the local thymic milieu. cells. Previous studies have demonstrated an important role for the thymus not only in central deletional tolerance, but also in the Results induction of peripheral tolerance by vascularized renal allografts in Thymic Involution with Age In Miniature Swine. We first examined juvenile miniature swine recipients. The same protocol did not induce the natural course of thymic involution with aging in naive minia- tolerance in thymectomized recipients nor in recipients beyond the ture swine (9). Right cervical thymic lobes were biopsied from 53 age of thymic involution. We subsequently reported that vascularized naive Massachusetts General Hospital (MGH) miniature swine of thymic lobe grafts from juvenile donors were capable of inducing different ages. The cortex and medulla in whole biopsy specimens tolerance in thymectomized juvenile hosts. However, the important containing at least 10 lobules were subjected to morphometric question remained whether aged, involuted thymus could also in- analysis by using NIH Image (Scion Image) software (10).
    [Show full text]